Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPT-302 + Ranibizumab in Wet AMD
NCT03345082Phase 2Completed
- Sponsor
- Opthea Limited
- Start
- Nov 2017
- Primary completion
- May 2019
- Modality
- Antibody Fragments, Fc-Fusion Proteins
- Countries
- 10
01
Overview
A Phase 2 trial of sozinibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Opthea Limited. Started Nov 2017; status: completed.
02
Drugs
sozinibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03345082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03345082.